Table 2.
Comparison of prevaccine and post-licensure prevalence of vaginal HPV by region, NHANES 2003–2014 (N=6,387)
| Prevaccine cycles (2003–2006) | Early post-licensure cycles (2007–2010) | Prevaccine &early PL p-value |
Late post-licensure cycles (2011–2014) | Prevaccine and late PL p-value |
|
|---|---|---|---|---|---|
| w% (95% CI) | w% (95% CI) | w% (95% CI) | |||
| Overall (n=6,387) | |||||
| Any HPV types | 44.4 (41.5–47.2) | 43.5 (40.6–46.4) | 0.68 | 41.7 (38.2–45.2) | 0.23 |
| Vaccine-type (6, 11, 16, 18) | 12.6 (11.2–14.0) | 11.6 (10.1–13.0) | 0.31 | 6.7 (5.2–8.2) | <0.001 |
| High-risk vaccine-type (16, 18) | 9.3 (7.9–10.6) | 9.1 (7.6–10.6) | 0.90 | 5.5 (4.2–6.8) | <0.001 |
| Nonvaccine-type (non-6, 11, 16, 18) | 41.7 (39.0–44.4) | 41.7 (38.6–44.8) | 0.99 | 40.6 (37.1–44.0) | 0.62 |
| Northeast (n=931) | |||||
| Any HPV types | 44.7 (39.0–50.4) | 45.3 (36.0–54.6) | 0.90 | 38.6 (33.9–43.4) | 0.05 |
| Vaccine-type (6, 11, 16, 18) | 12.3 (7.6–16.9) | 11.1 (7.2–15.0) | 0.66 | 3.5 (3.0–4.0) | <0.001 |
| High-risk vaccine-type (16, 18) | 8.1 (5.3–10.9) | 9.0 (4.6–13.4) | 0.69 | 3.3 (2.8–3.7) | <0.001 |
| Nonvaccine-type (non-6, 11, 16, 18) | 40.4 (35.1–45.8) | 41.2 (35.6–54.4) | 0.40 | 38.2 (33.4–43.0) | 0.46 |
| Midwest (n=1,259) | |||||
| Any HPV types | 40.6 (34.4–46.9) | 46.0 (40.2–51.8) | 0.17 | 38.9 (35.8–42.1) | 0.57 |
| Vaccine-type (6, 11, 16, 18) | 14.4 (12.7–16.1) | 12.6 (9.9–15.4) | 0.24 | 8.6 (5.2–12.0) | 0.002 |
| High-risk vaccine-type (16, 18) | 8.2 (6.7–9.7) | 10.1 (7.5–12.8) | 0.16 | 7.3 (4.0–10.6) | 0.57 |
| Nonvaccine-type (non-6, 11, 16, 18) | 38.8 (33.8–43.9) | 43.2 (37.7–48.6) | 0.20 | 38.0 (35.0–41.1) | 0.78 |
| South (n=2.458) | |||||
| Any HPV types | 48.7 (42.9–54.6) | 44.1 (39.5–48.7) | 0.20 | 47.6 (42.2–53.0) | 0.77 |
| Vaccine-type (6, 11, 16, 18) | 12.2 (9.6–14.8) | 12.7 (9.9–15.4) | 0.78 | 8.6 (6.2–11.1) | 0.05 |
| High-risk vaccine-type (16, 18) | 10.0 (7.3–12.7) | 9.4 (6.6–12.1) | 0.72 | 6.8 (5.2–8.5) | 0.03 |
| Nonvaccine-type (non-6, 11, 16, 18) | 47.0 (40.8–53.2) | 42.3 (37.0–47.5) | 0.23 | 45.9 (40.4–51.4) | 0.79 |
| West (n=1,739) | |||||
| Any HPV types | 41.6 (37.7–45.6) | 38.8 (34.0–43.6) | 0.37 | 37.9 (29.9–46.0) | 0.39 |
| Vaccine-type (6, 11, 16, 18) | 11.8 (9.9–13.7) | 9.0 (5.5–12.5) | 0.18 | 4.8 (2.6–7.0) | <0.001 |
| High-risk vaccine-type (16, 18) | 10.0 (8.5–11.6) | 7.9 (4.2–11.6) | 0.31 | 3.9 (2.1–5.6) | <0.001 |
| Nonvaccine-type (non-6, 11, 16, 18) | 37.7 (33.5–41.8) | 37.3 (32.4–42.3) | 0.90 | 37.0 (28.9–45.1) | 0.87 |
Any HPVgenotype includes types 6, 11, 16, 18, 26, 31, 33, 35, 39, 40, 42, 45, 51, 52, 53, 54, 55, 56, 58, 59, 61, 62, 64, 66, 67, 68, 69, 70, 71, 72, 73, 81, 82, 83, 84, 89, and IS39.
PL=post-licensure; HPV=human papillomavirus; NHANES=National Health and Nutrition Examination Survey